Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for CZMWY and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for CZMWY and 80,000+ other tickers.
See exactly how CZMWY's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for CZMWY and 80,000+ other tickers.
Carl Zeiss Meditec AG functions as a prominent global medical technology firm, conducting its operations across Germany, other European nations, the United States, and various Asian markets. Its business is organized into two principal divisions: Ophthalmic Devices and Microsurgery. The Ophthalmic Devices segment provides an array of products and solutions tailored for the diagnosis and therapeutic management of ocular conditions, including specialized systems and essential consumables for cataract, retinal, and refractive surgical procedures. This division serves ophthalmologists…
Carl Zeiss Meditec AG (CZMWY) Q3 2026 Earnings Call Transcript
Carl Zeiss Meditec AG (CZMWY) Q2 2026 Earnings Call Transcript
Carl Zeiss Meditec ETR: AFX reported weaker first-half results for fiscal 2025/2026 and outlined a broad restructuring plan aimed at restoring profitability over the next three years, as management pointed to currency headwinds, soft equipment demand and pressure in China's intraocular lens business.
Carl Zeiss Meditec AG (OTCMKTS:CZMWY - Get Free Report) was the recipient of a large growth in short interest in April. As of April 15th, there was short interest totaling 5,102 shares, a growth of 89.7% from the March 31st total of 2,690 shares. Based on an average daily volume of 8,140 shares, the short-interest
Carl Zeiss Meditec AG is rated a "Buy" despite recent operational weakness and geopolitical headwinds, especially in Asia-Pacific and North America. Sales declined 4.8% in Q1, with margin compression and a suspended 2025/2026 outlook due to weak demand across Asia-Pacific and North America. CZMWF now trades at a significant discount to peers, with a 2026 price target of $39.26, implying ~20% upside against a discounted multiple.